Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good post, IB.
Well-reasoned, and I agree with just about all of it. Thanks for the input.
DONT BELIEVE WHAT YOU READ
My wife became a citizen YESTERDAY from Germany. Her son is a career PT there and her cousin is a recently retired GP.
I cant begin to tell you the medical horror stories they all relate..from wait time for DX to scheduling follow up tests and refusal of treatments and "expensive" medicines.
People around the world come here for serious care if they can afford too.
Canadians spend a Gigantic amount of Money for care here.
Can't get it in Canada
The world depends on us.
Oh, and the American SAFTEY NET Takes Care of ALL and Fast.
we have the best healthcare for the patient in the world.
I pay $2 for 60 days of simvastin
I pay $4 for 90 days of BP med
GOOD RX....FREE (NO MEMBERSHIP) and any good pharma place compares GOOD=RX to whatever insurance you have for the lower price.
No need to choose...
I am still not sure whether it was incompetence or corruption.
Intellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets System
https://www.intellipharmaceutics.com/news-media/press-releases/detail/196/intellipharmaceutics-receives-nasdaq-listing-determination
TORONTO, ON / ACCESSWIRE / March 19, 2019 / Intellipharmaceutics International Inc. (Nasdaq and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced that today the Company received formal notice that the Nasdaq Hearings Panel had determined to delist the Company's shares from The Nasdaq Stock Market LLC ("Nasdaq") based upon the Company's non-compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). The suspension of trading on Nasdaq will take effect with the open of business on Thursday, March 21, 2019.
Intellipharmaceutics will remain a public company and anticipates that its shares will be eligible to trade publicly on the OTCQB Venture Market, which is operated by the OTC Markets Group Inc., commencing on Thursday, March 21, 2019. The Company's stock will retain the ticker symbol "IPCI." The Company is also listed on the Toronto Stock Exchange and the Company's non-compliance with Nasdaq's bid price requirement does not impact the Company's listing or trading status on that exchange.
The notice indicated that Nasdaq will ultimately effect the formal delisting of the Company's shares by filing a Form 25 - Notification of Delisting with the Securities and Exchange Commission after all applicable Nasdaq appeal and review periods have expired. The Company does not intend to appeal the delisting determination.
Wow. Wait, what?
It is highly unlikely we get a CRL because this is a generic of Adderall. FDA requirements are far less strenuous. It is not like a brand new unknown drug.
Nobody who has done any DD says that.
ELTP wont benefit from Isradipine approval for PD?
Here's the case being made:
Quote from numbersarefun:
I do not think Elite Pharmaceuticals has ever said anything. The hype is that ELTP would benefit from isradipine for parkinson's research.
According to parkinson-study-group.org homepage, "The PSG has partnered with numerous pharmaceutical companies and the National Institutes of Health (NIH) in bringing new drugs for Parkinson disease to the market including pramipexole, entacapone, rotigotine and rasagiline." Those are expensive drugs called Mirapex, Comtan, Neupro, and Azilect.
Isradipine for parkinson would most likely be manufactured and marketed, under a brand name, by a pharmaceutical. That is probably years away, assuming it works. Don't you need two Phase 3 studies to file an NDA?
Also, isradipine for parkinson has a pending patent by the inventor. I assume the patent holder would license it to some pharmaceutical to gain financially from the research.
Which fact about ELTP and isradipine do you not believe? Is it that Elite is one of two companies that currently manufactures isradipine? Is it that isradipine for Parkinson's Disease passed a Phase 2 safety study, called STEADYPD-II? Do you dispute that a Phase 3 efficacy study of isradipine for Parkinson's (STEADYPD-III) has been done and the results will be released in early May?
Comprehensive DD re: isradipine expectations
I'm still working on getting this info into nice looking spreadsheet format, but I wanted to share with everyone the comprehensive, exhaustive DD I have done on what we can expect for ELTP if STEADYPD-III results are favorable. I have listed below every previous example of when a little-used generic blood pressure drug with only two manufacturers is re-purposed to delay progression of a severely debilitating neuro-degenerative disease with supporting Phase 2 and Phase 3 studies entirely paid for by a private foundation and the NIH. Check it out:
1.
Hope this helps! Have a great weekend.
Friday afternoon...
...eight days after NASDAQ delisting hearing. We could see news after closing. Should I put my chips on red or on black? Which is better: delisting to the OTC -or- NASDAQ extension with reverse split? Hard to say either option is a win. I think I'll keep my chips and hit the bar instead.
No need to mark this post.
I hope I'm wrong but as said before, IMO the Isradipine trial is a bust. I believe the results are definitely known by now and we would start to see it reflected in the volume/SP. Mark this post...
I am guessing 20-25M shares will be sold for about $3-5M.
Wee: just to be clear - presentations were due October 2018 for consideration so for this to be included at this late time it must be very good; my correct on the assumption?
You think they already know the results?
If they already know the results and they are horrible, would they even be releasing the results during this meeting?
Are they purposely releasing the results during this meeting because they are good/great?
What does your gut tell you?
We have a date...
https://scienceofparkinsons.com/2019/02/28/february-2019/#more-52900
STEADY-PD III (isradipine) clinical trial results will be released at the 2019 American Academy of Neurology meeting in Philadephia on the 4th-10th May, 2019.
are you saying those solvents wouldn't affect he naltrexone beads, only the oxy beads? And are we to infer those same three solvents work the same on Sequest beads as the Troxyca/Embeda tablets?
One unique exception appears to be the use of Solvents F, G, H and O on crushed pellets, which selectively extracts naltrexone from oxycodone.
This is further supported by the ability of solvent P to selectively extract oxycodone even in crushed tablets. Solvents I appear to extract oxycodone selectively from crushed tablets.
no addicted person could afford the equipment or have the knowledge it would take to separate the beads. It is absolutely not going to happen on the street.
Panelists were also concerned that the drug, while resistant to abuse via crushing and several types of dissolution, appeared to be easily dissolved in three commonly available solvents that are safe for consumption and easy to obtain, although it might take some time to do so.
"Once the recipe is out there, it doesn't matter if they had 5,000 data points that didn't work," said panelist Jeanmarie Perrone, MD, of the University of Pennsylvania in Philadelphia. "Once you get the one that does work, it will be the one that proliferates, and it's pretty simple based on what we've looked at."
If Elite's Tech can be defeated, where does that leave SequestOx and the complete ART Opioid pipeline?
I disagree.
What everyone needs to understand is that the FDA is always changing what is needed during the approval process, this is no way in any fault of Elite's.
Alternatively, common solvents A and L to N, are generally unable to extract oxycodone
from naltrexone selectively in crushed pellets. One unique exception appears to be the
use of Solvents F, G, H and O on crushed pellets, which selectively extracts naltrexone
from oxycodone. Of the common solvents I and P, solvent P selectively extracts the
oxycodone in a manner that appears dependent on the intrinsic solubility of the two APIs,
not on the delayed release of naltrexone by the sequestering membrane. This is further
supported by the ability of solvent P to selectively extract oxycodone even in crushed
tablets. Solvents I appear to extract oxycodone selectively from crushed tablets
Complete nonsense.
200 Americans died of an overdose of opioid-based pain killer every day. Not junkies! Fathers and mothers of families, pensioners, ... 200 per day!
Those pesky material facts...
How many class action suits are pending at this time? That's probably where the $12 million went... lawyers for the Odidi's.
https://ih.advfn.com/stock-market/NASDAQ/intellipharmaceutics-international-inc-mm-IPCI/stock-news/79352433/prospectus-filed-pursuant-to-rule-424b3-424b3
On February 21, 2019, the Company and its CEO, Dr. Isa Odidi, received a Statement of Claim concerning an action against them in the Superior Court of Justice of Ontario under the caption Victor Romita, plaintiff, and Intellipharmaceutics International Inc and Isa Odidi, defendants, . The action seeks certification as a class action and alleges that certain public statements made by the Company in the period February 29, 2016 to July 26, 2017 knowingly or negligently contained or omitted material facts concerning the Company’s NDA for Oxycodone ER abuse-deterrent oxycodone hydrochloride extended release tablets. The plaintiff alleges that he suffered loss and damages as a result of trading in the Company’s shares on the Toronto Stock Exchange during the above-noted period. The claim seeks, among other remedies, unspecified damages, legal fees and court and other costs as the court may permit. At this time, the action has not been certified as a class action. The Company intends to vigorously defend against the claims asserted in this action.
More States Say Docs Must Offer Naloxone With Opioids
But is co-prescribing the solution?
Don’t be a dumbass. Only idiots pay $4500 for opioid overdose protection! You can make your own WeeZuhl-brand Opioid Overdose Protection (“Oops”) Nasal spray for just a few dollars! Although WeeZuhl-brand Oops Nasal Spray has never been tested in any way, it SHOULD work! And let’s face it, P.O.O.P., as a regular heroin injector, you’re probably not a big stickler for generally-accepted standards of safety and efficacy. Now let’s get busy. You’ll need a few supplies. You need one 3.5 ounce bottle of saline nasal spray (~$5) and two tablets of Elite Pharmaceuticals generic naltrexone 50mg (~$2/tab. You’ll need a prescription for these).
don’t be a heroin addict AND a chump. $4500 Evzio vs. $10 WeeZuhl-brand Oops Nasal Spray is a no-brainer. But remember! Any kind of opioid overdose protection system will only work if you use the Buddy System, and if your buddy is a heroin-addled dufus who does not know what to do then you are still dead. Good luck!
what's your take about the de-delisting ?
RE: Intellipharmaceutics International Inc.
Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following
information in connection with its Annual and Special Meeting of Shareholders:
Date of meeting: April 30, 2019
Record date for notice: March 12, 2019
Record date for voting: March 12, 2019
Beneficial ownership determination date: March 12, 2019
Securities entitled to notice: Common Shares
fabius haiku 4u
As per today Bloomberg's IPCI ownership page there is no sign of Boyd and its fund anymore.
Old but good: REPOST 5/14/15
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=113680277
Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of Enrollment
9:30 AM ET, 05/14/2015 - PR Newswire
A prior interim analysis conducted in 2011, as well as a primary efficacy analysis conducted in 2013, pointed to a benefit of the AE37 vaccine in patients not receiving Herceptin and, in particular, patients with triple negative breast cancer. This latter group represents a patient population of high unmet need. The present study continues to show a trend in this population, with a 35% reduction in the relative risk of recurrence in patients receiving the AE37 vaccine.
Congratulations to the Antigen team. This shows there is great promise for AE37, especially for this tough to manage population with triple-negative breast cancer. Nothing else has shown anything near this effective for this group. No way this can be let alone. I think we can expect to hear more soon. I suspect the next step will be a combination trial with at least one other peptide. I suspect it will be with Dr. Mittendorf as primary investigator.
Question: Will the new peptide(s) be hybrid vaccine with Ii-key moeity? I would think so.
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
Results: There were no clinicopathologic differences between groups in the 298 enrolled pts (VG = 153, CG = 145). The vaccine is safe and well tolerated. After a median f/u of 55 mo, there was a trend toward improved DFS in the VG among stage IIB/III pts (VG, n = 73, DFS 82% vs CG, n = 61, 67%, HR = 0.48, p = 0.06) and those with low HER2 expression (HER2 LE, VG, n = 68, 89% vs CG, n = 66, 51%, HR = 0.47, p = 0.1). Improved DFS in the VG was documented in patients with both stage IIB/III disease and HER2 LE (VG, n = 39, 90% vs CG, n = 38, 32%, HR 0.3, p = 0.02) and triple negative (TNBC) pts (VG, n = 21, 89% vs CG, n = 21, 0%, HR 0.26, p = 0.05).
You are welcome.
Getting 510K clearance is not trivial, and it does mean that the FDA agrees that the product is fit for it's intended use.
FDA’s ‘flawed’ device pathway persists with industry backing
By MATTHEW PERRONENovember 27, 2018
WASHINGTON (AP) — Roughly 3,000 medical devices enter the U.S. market every year through a system that generally requires little or no patient testing to verify safety and effectiveness.
Unlike new pharmaceuticals, most medical devices reviewed by the Food and Drug Administration are cleared based on similarities to already-approved devices, not specific clinical trial testing.
The agency’s streamlined review system has been blamed for a string of defective devices coming to market, including hip replacements that can leach metal debris into patients’ joints and pelvic mesh that can puncture internal organs. Still, the 42-year-old system persists, in part because of the power of the medical device lobby, which floods Washington with hundreds of lobbyists and millions of dollars.
Clear or approved doesnt matter.
What are you talking about?
I think so too, but am less positive on the outcome of the trial. All other calcium blockers have failed.
I don't know how else to say it.
Wrong.. According to GNBT's Press release they were FDA Cleared
Very helpful but I already know this.
My backgroud is Healthcare and Healthcare IT.
1. I dont need to watch my language.
2. Yes Elleagen is a topical solution
3. Yes it still needs FDA approval. It still needs rigorous testing and FDA regulation for many reasons.
4. Now that they have FDA approval. It can be safely and confidently provided and an option to patients. Especially victims who have been hurt in various accidents. Theres not much space in woundcare fields where people have solutions for treatments. But improved solutions are very important.
Watch your language.
Definitely not a scam. FDA Approval is tough to get and costs time and money. GNBT has proof from the FDA its 100% legit.
More than 30% of completers being retroactively excluded is enough all by itself to invalidate the entire study. The authors repeatedly say further studies are needed with alternative methodologies. This product may be helpful to speed up healing for certain types of wounds, but it is not better than standard care for most types of wounds. And this was published in 2011, so the standard of care for wounds has changed substantially in that time period, especially with prolific usage of wound vacs. The MATRIX study data is old, flawed, and proves nothing unequivocally. Anybody who describes this data as impressive or robust or as proof of anything is either not capable of interpreting scientific data or is intentionally misrepresenting the scientific data. Anybody can read it and see for themselves...
I agree, this is sad and lame.
people posing as doctors
I hear this occasionally...
Avoiding opioids is imperative to the well-being of chronic pain patients.
Thankfully, there are non-narcotic solutions to chronic pain. Why even start with a painkiller when there are other ways?
NASDAQ Extension until March 7
At a hearing held on January 10, 2019, the Company presented its plan to regain and maintain compliance with Nasdaq’s continued listing requirements. Following the March 7, 2019 deadline, the Panel will determine whether a further extension period is warranted in the event the Company has not regained compliance.
Weezuhl,
Do you consider it a fantasy that Sungen or its parent company would buy Elite?
Do you agree that Nasrat must sell the company in order to cash out his shares?
How else if not via a buyout?
Really, Ok what did this mean:
Aug 04, 2004
Elite Pharmaceuticals Announces Exclusive Option To License Its Technology Granted To Purdue Pharma Has Lapsed
Heads up, stay tuned.
Friday afternoon news dump? In May 2018, it took 4 business days after the NASDAQ hearing for IPCI to PR that they had received an extension. Today is day #6 after the hearing on 1/10/19.
The topic was Purdue buying Elite, people. The topic was not about a licensing agreement with Elite. 2 monumentally different concepts. Please stop conflating.
My Guess is Purdue Will Buy This
Everyone, please notice Elite has branched out in the last 14.5 years, not to mention many companies have even changed their minds over the course of 14.5 years.